Phase II Clinical Study on SyB L-0501 [bendamustine] in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma (Multicenter, Open-Label Study).

Trial Profile

Phase II Clinical Study on SyB L-0501 [bendamustine] in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma (Multicenter, Open-Label Study).

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2010

At a glance

  • Drugs Bendamustine (Primary)
  • Indications Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors SymBio Pharmaceuticals
  • Most Recent Events

    • 21 May 2008 The projected timeline for NDA filing is now expected to be in the 4th quarter of 2009, due to the rapid pace of patient enrollment, according to a SymBio Pharmaceuticals media release.
    • 21 May 2008 Enrollment of study patients with mantle cell lymphoma is progressing at a good pace; target numbers are expected to be reached in the near future, according to a SymBio Pharmaceuticals .
    • 21 May 2008 Enrollment of patients with non-Hodgkin's lymphoma completed ahead of the predicted 15 months and within 5 months of study start, according to a SymBio Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top